diabetestalk.net

Januvia Pancreatitis Lawsuit

Januvia & Janumet Lawsuit News

Januvia & Janumet Lawsuit News

Home Januvia & Janumet Pancreatic Cancer Lawsuit Lawyer Januvia & Janumet Pancreatic Cancer Lawsuit Lawyer If you have type 2 diabetes and you were given the drugs Januvia or Janumet, your life was put at risk. These drugs are now known to dramatically increase the risk of pancreatitis, or inflammation of the pancreasa condition that can lead to pancreatic cancer. The FDA has received numerous reports of diabetes patients being hospitalized for pancreatitis or being diagnosed with cancer after using Januvia. Lawsuits now state that patients were not given proper warning, and that doctors were not notified of the risk. People with diabetes were endangered by the very drugs that were supposed to help them. At John Foy & Associates, were taking a stand against this sort of reckless behavior from the pharmaceutical industry. We are investigating possible lawsuits against Merck, the manufacturer of Januvia and Janumet. We would like to speak to you if you or a loved one have taken either of these drugs and suffered from adverse effects such as pancreatic cancer, pancreatitis, thyroid cancer, heart failure, or kidney failure, you or your family may be eligible for a substantial financial recovery. John Foy & Associates is one of the largest, most experienced medical injury law firms in the country. We believe patients have rights and that drugs should do what they say they dowithout unexpected side effects. Let us discuss your case with you for free. Call us at 404-400-4000 and get your free consultation today. Januvia is the brand name of a diabetes drug called sitagliptin, made by Merck & Co. Its part of a new class of diabetes drugs for type 2 diabetics. These drugs affect an enzyme called dipeptidyl peptidase-4 (DPP-4), and are known as DPP-4 inhibitors. In type 2 diabet Continue reading >>

All About The Januvia And Victoza Pancreatic Cancer Lawsuits

All About The Januvia And Victoza Pancreatic Cancer Lawsuits

The federal court overseeing the nationwide Januvia and Victozia pancreatic cancer litigation appointed Mr. Kennerly to the “Plaintiffs’ Steering Committee,” the group of plaintiffs’ lawyers responsible for building the case against Merck, the manufacturer of Januvia and Janumet, and Novo Nordisk, the manufacturer of Victoza. I’ve written several posts going back to 2012 about the link between Januvia and pancreatic cancer. Below is an brief summary of the science behind the cases. As of January 2018, there are several different groups of Januvia lawsuits: a federal multidistrict litigation based in the federal court in San Diego, a state consolidated litigation in Los Angeles, and scattered lawsuits filed in other states. No jury trials have been held. Correspondingly, there have been no Januvia or Victoza lawsuit settlements: the drug companies still vehemently deny any responsibility, and the litigation is simply too new for any settlement discussions yet. I represent a wide variety of clients who developed pancreatic cancer after taking Januvia, clients on both sides of the country and everywhere in between, clients ranging in age from their forties to their eighties. Our law firm has filed Januvia and Victoza cases in all of the courts identified above, and we are continuing to file cases. We review cases free of charge, and we represent clients on a contingent fee. (That is, we pay all costs on the case, and only charge a fee if we recover compensation.) The Causes Of Pancreatic Cancer, And The Cancer’s Relationship To Diabetes If you’re reading this page, then likely you or someone you know was diagnosed with pancreatic cancer. You already know that the prognosis is typically poor, even with aggressive treatment. Pancreatic cancer is typically asymp Continue reading >>

Januvia Lawsuit | Januvia Pancreatic Cancer | Morgan & Morgan

Januvia Lawsuit | Januvia Pancreatic Cancer | Morgan & Morgan

The attorneys at Morgan and Morgan are investigating claims on behalf of Januvia users that have been diagnosed with pancreatic cancer. Various academic and post-marketing studies have established a possible link between Januvia (sitagliptin) and pancreatic cancer. This link is particularly troubling because pancreatic cancer is one of the most lethal malignant diseases, due to the high rate of advanced stage disease at the time of diagnosis and the lack of effective medical therapies. If you or a loved one was diagnosed with pancreatic cancer aftertaking Januvia, do not hesitate to contact our attorneys today, free of charge, to learn more about your legal rights. You may be able to file a lawsuit against the manufacturer to recover compensation for medical bills, lost wages, pain and suffering, and other damages. To contact us today, please fill out our free, no obligation case review form . Merck is facing a number of lawsuits claiming that Januvia is a flawed and defective product , and increases the risk of pancreatic cancer in users. These suits allege that: Merck knew Janvuia could pose a risk of pancreatic cancer and keptthis information from patients and doctors The warnings on Januvia are inadequate and do not even mentionpancreatic cancer Merck failed to tell doctors to monitor Januvia users for signs ofchanges within the pancreas Januvia poses an extreme risk and its benefits do not outweigh thisrisk Rather than pull the drug from the market or issue stronger warnings,Merck continues to promote Januvia as a safe and effective treatment Merck did not perform adequate safety tests Merck over-promoted Januvia and under-warned about its risks These suits are seeking a number of damages, including but not limited to lost income, diminishment of earning capacity, Continue reading >>

Diabetic Drugs, Januvia And Byetta Lawsuits Continue To Grow

Diabetic Drugs, Januvia And Byetta Lawsuits Continue To Grow

Home Blog Diabetic Drugs, Januvia and Byetta Lawsuits Continue to Grow Diabetic Drugs, Januvia and Byetta Lawsuits Continue to Grow In August 2013, the increasing number of lawsuits against drug manufacturers, Merck and Amylin led to the creation of a multidistrict litigation in the Southern District of California. Plaintiffs claim in diabetic drug lawsuits that involve Januvia and Byetta cause side effects such as pancreatic cancer and pancreatitis. Januvia and Byetta are often prescribed to treat Type 2 diabetes by reducing blood sugar levels. The FDA approved Januvia in 2006 and Byetta in 2005. However, in 2007, the FDA warned that the drugs may cause pancreatic diseases. The warning was based on reports that at least 30 users of Byetta were diagnosed with acute pancreatitis. From 2006 to 2009, 88 cases of acute pancreatitis were linked to Januvia. Half of these patients indicated that pancreatic inflammation diminished after they stopped taking Januvia. Lawsuits are continuing to grow and filed directly to the MDL. In January 2015, a Plaintiff in California filed a lawsuit claiming that Byetta caused him to develop thyroid cancer. Although the majority of the cases involve pancreatic cancer, linking Byetta to thyroid cancer is the common theme of Byettas connection to a cancer diagnosis. Another Plaintiff in Georgia, the successor of a Januvia user who died of pancreatic cancer a week after the diagnosis, is one of many recently being centralized in the MDL. Plaintiffs are charging Merck (manufacturer of Januvia) and Amylin (manufacturer of Byetta) for failing to provide adequate warning of the risks involved and knowingly promoting the dangerous drugs to the public. As of February 2015, parties in the MDL are lining up their respective experts. As pharmaceutical d Continue reading >>

Januvia Pancreatic Cancer Lawsuits | Janumet Attorney

Januvia Pancreatic Cancer Lawsuits | Janumet Attorney

Januvia & Janumet Pancreatic Cancer Lawsuits We are investigating potential lawsuits throughout the United States for claims on behalf of victims who took the drugs and have suffered from pancreatic cancer. These lawsuits will allege product liability, negligence, and failure to warn claims against Merck & Co., Inc., the manufacturer. These drugs used to treat specific types of diabetes. Januvia is a prescribed pill taken once-daily to help manage blood sugar in adults with type-2 diabetes. Janumet is a prescription used to manage blood sugar in adults with type-2 diabetes mellitus. Type-2 diabetes (also known as adult-onset diabetes and non-insulin dependent diabetes) affects the bodys metabolization of sugar. With type-2 diabetes, the body is either resistant to the effects of insulin or does not manufacture enough insulin. The effect is that the body cannot maintain a normal glucose level. Januvia and Janumet are new classes of drugs known as sitagliptin which are dipeptidyl peptidase-4 (DPP-4) inhibitors or blockers. These DPP-4 blockers help the body to manage blood sugar levels. They increase the amount of insulin manufactured by the pancreas when blood sugars are their highest (usually after eating). They also lower the amount of sugar manufactured by the liver after eating, when the body does not need it. What are the Warning Signs and Dangers of Januvia and Janumet? Januvia and Janumet may cause acute pancreatitis and, as you will see below, pancreatic cancer. On September 25, 2009, the FDA issued a warning to healthcare professionals that the drugs have been associated with 88 cases of acute pancreatitis (including hemorrhagic and necrotizing pancreatitis) by patients using sitagliptin. These 88 cases were found using the FDAs post-market surveillance and occ Continue reading >>

Januvia Pancreatic Cancer Lawsuit

Januvia Pancreatic Cancer Lawsuit

Byetta, Victoza, Januvia, and Janumet are a new class of diabetes medications, known as Incretin Mimetics . Unfortunately, Byetta, Victoza, Januvia, and Janumet have been linked to an increased risk of pancreatitis and pancreatic cancer. Byetta, Victoza, Januvia, and Janumet are a new class of diabetes medications, known as Incretin Mimetics. Unfortunately, Byetta, Victoza, Januvia, and Janumet have been linked to an increased risk of pancreatitis and pancreatic cancer. According to injured plaintiffs, the drug makers knew these medications may increase the development of pancreatic cancer, but they failed to warn diabetic patients and the doctors. The diabetes drug Januvia (sitagliptin) controls blood-sugar levels by stimulating the pancreas to release more insulin. Recent studies suggest it could over-stimulate the pancreas leading to inflammation, known as pancreatitis, or may cause pancreatic cancer. As the FDA investigates these risks, hundreds of lawsuits have been filed and centralized in one federal court in California. Hundreds of Pancreatic Cancer Lawsuits Centralized in California In July 2013, the JPML judges centralized all pancreatic cancer cases from the use of Byetta, Januvia, and Victoza. By January 2016, over 750 lawsuits were transferred to the U.S. District Court for the Southern District of California, overseen by Judge Antony Battaglia: In Re: Incretin Mimetics Products Liability Litigation MDL . Following coordinated discovery and pretrial proceedings, Judge Battaglia granted a motion for summary judgment in 2015, finding that the claims were pre-empted by federal law, in other words, that these companies were immune from lawsuits. Plaintiffs appealed that decision to the U.S. Court of Appeals for the Ninth Circuit, which issued an opinion on Dec Continue reading >>

Januvia Class Action Lawsuit Claims & Cash Settlements Attorneys Ready

Januvia Class Action Lawsuit Claims & Cash Settlements Attorneys Ready

Cases associated with Januivaare acute, and brief. In UCLA, a clinical study discovered that taking Januivaincreases the risk of pancreatitis six-fold, and that cases usually develop in less than two months. Januivais also linked to pancreatic cancer. Pancreatic cancer tumors can grow without symptoms and sometimes arent detected until the cancer gets more serious. According to a study done at UCLA, patients taking Januivahave more than double the risk of developing pancreatic cancer. The longer a patient has been taking the drug, the higher the risk of cancer. Alabama (AL), Alaska (AK), Arizona (AZ), Arkansas (AR), California (CA), Colorado (CO), Connecticut (CT), Delaware (DE), Florida (FL), Georgia (GA), Hawaii (HI), Idaho (ID), Illinois (IL), Indiana (IN), Iowa (IA), Kansas (KS), Kentucky (KY), Louisiana (LA), Maine (ME), Maryland (MD), Massachusetts (MA), Michigan (MI), Minnesota (MN), Mississippi (MS), Missouri (MO), Montana (MT), Nebraska (NE), Nevada (NV), New Hampshire (NH), New Jersey (NJ), New Mexico (NM), New York (NY), North Carolina (NC), North Dakota (ND), Ohio(OH), Oklahoma (OK), Oregon (OR), Pennsylvania (PA), Rhode Island (RI), South Carolina (SC), South Dakota (SD), Tennessee (TN), Texas (TX), Utah (UT), Vermont (VT), Virginia (VI), Washington (WA), Washington DC (DC), West Virginia (WV), Wisconsin (WI), Wyoming (WY) Our lawyers and attorneys can provide information on how to file Januvia lawsuits in the following cities: New York, Chicago, Philadelphia, Detroit, Indianapolis, Columbus, Baltimore, Boston, Seattle, Washington, Milwaukee, Denver, Louisville, Los Angeles, Las Vegas, Nashville, Oklahoma City, Portland, Phoenix, Houston, Tucson, Albuquerque, Atlanta, San Antonio, San Diego, San Francisco, Dallas, Colorado Springs, Arlington, Wichita, Long Continue reading >>

Januvia & Byetta Lawsuit

Januvia & Byetta Lawsuit

Studies document pancreatitis and pancreatic cancer In 2011, physicians reviewed reports made to the FDA concerning harmful side effects caused by Januvia and Byetta use. The doctors published their findings in a peer-reviewed journal, noting that both pancreatitis and pancreatic cancer had been reported as complications. Two years later, the Journal of the American Medical Association Internal Medicine published a study based on data from a very large health insurance plan. The article reported that Type 2 diabetes patients using Januvia or Byetta were more than twice as likely to be hospitalized for acute pancreatitis as were control group patients who did not use either of the drugs. Pancreatitis, in turn, is a risk factor for pancreatic cancer. In April 2013, the non-profit Institute for Safe Medicine Practices reviewed FDA data concerning complications from use of Januvia and Byetta compared to side effects from other diabetes drugs. The study found that the odds of pancreatitis among Januvia users were more than 20 times higher than among the control group; among Byetta users the pancreatitis odds were over 28 times higher. For pancreatic cancer, the odds for Januvia users were more than 13 times higher than among the control group. Byetta users were over 30 times more likely to report pancreatic cancer. The odds of thyroid cancer were 15 times higher among Byetta users. Litigation mounts alleging pancreatic cancer Patients who have been seriously injured after taking the incretin mimetics have filed Byetta and Januvia lawsuits around the country. In most cases, those injured seek compensation for their pain and suffering, ongoing treatment for their serious conditions, and any wages they may have lost as a result of their injuries. Because the cases involve simi Continue reading >>

Januvia Class Action Lawsuit Information

Januvia Class Action Lawsuit Information

The diabetes drug Januvia (sitagliptin) controls blood-sugar levels by stimulating the pancreas to make more insulin. Unfortunately, recent studies suggest it could over-stimulate the pancreas and lead to inflammation, pancreatitis, or even pancreatic cancer. As the FDA investigates these risks, hundreds of lawsuits have been filed and centralized in one federal court in California. The Schmidt Firm, PLLC is currently accepting Januvia induced injury cases in all 50 states. If you or somebody you know was diagnosed with pancreatic cancer, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call us toll-free 24 hours a day at (866) 920-0753. In the United States, most large and complex drug injury litigation is resolved in a Multi-District Litigation (MDL) rather than a class action. This is a federal action that allows class actions and individual lawsuits to be transferred from many state courts into one federal court. Unlike a class action, lawsuits transferred into an MDL remain independent. Hundreds of Lawsuits Centralized in California In July 2013, federal judges issued an order (PDF) to centralize all lawsuits involving pancreatic side effects of diabetes drugs in the incretin mimetic class, including Januvia. Plaintiffs in the litigation allege that drug-companies downplayed the risk of pancreatic cancer. By January 2016, over 750 lawsuits were transferred into the U.S. District Court for the Southern District of California, under Judge Antony J. Battaglia: In Re: Incretin Mimetics Products Liability Litigation MDL. No one knows if Januvia causes pancreatic cancer , but evidence of a potential risk has been growing for years. Januvia treats diabetes by increasing ho Continue reading >>

Januvia Pancreatic Cancer Information & Litigation Updates

Januvia Pancreatic Cancer Information & Litigation Updates

The Januvia injury case attorneys at the Drug Law Center are currently representing many patients who have suffered serious harm or families who lost a loved one after taking the antidiabetic medication. Januvia (sitagliptin) is a prescription oral diabetes drug developed by Merck & Company to control the bodys blood sugar levels. The drug is effective because it regulates insulin levels in the body after eating. The medication has been approved to treat Type II diabetes and is not effective for Type I diabetes. The FDA approved the medication in October 2006 to be used alone or concomitantly with other diabetic drugs. The Food and Drug Administration (FDA) first approved Januvia in its generic form sitagliptin phosphate in October 2006 to be available to consumers in tablet form for the treatment of Type II diabetes. The first brand label version of sitagliptin manufactured by Merck & Company was called Janumet. The medication is a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor drug designed to be used alone or concomitantly with exercise and diet. Doctors often prescribe Januvia to improve the patients glycemic control when treating their Type II diabetes mellitus. Januvia has been available in the medical marketplace since 2006. Even before it was launched and made available to the public, the popular Type II diabetes medication had been linked to serious life-threatening side effects. these include thyroid cancer, pancreatic cancer, and pancreatitis. As early as 2009, The Food and Drug Administration identified nearly 90 cases of pancreatitis involving Janumet and Januvia between October 2006 and February 2009 alone. Two of these cases involved necrotizing and hemorrhagic pancreatitis. By 2011, The Federal agency announced to the public that they would be evaluating unpu Continue reading >>

Januvia Pancreatic Cancer, Januvia Thyroid Cancer

Januvia Pancreatic Cancer, Januvia Thyroid Cancer

Januvia is a drug prescribed to help treat adults with type-2 diabetes. In September 25, 2009 the FDA issued a revision to the warning label of the drug Januvia or Janumet--a combination drug comprised of Januvia and Metformin--regarding Januvia side effects, including Januvia pancreatic cancer and Januvia thyroid cancer. If you have taken the Januvia diabetes drug and are concerned about Januvia and cancer and/or Januvia and pancreatitis, you should speak with an attorney about a possible Januvia lawsuit. Januvia is a type 2 diabetes that is also available in a combination pill (known as Janumet) that contains the drug metformin. (Janumet 50/500 is 500mg of Metformin plus 50mg of Januvia.) Januvia (sitagliptin) and Janumet (sitagliptin/metformin) are the first in a new class of oral diabetes medications, called dipeptidyl peptidase-4 (DPP-4) inhibitors that improve blood sugar control in patients with type 2 diabetes. Januvia - which works by affecting different cells in the pancreas - first came on the market in late 2006. However, after that release, the FDA received dozens of reports of pancreatitis from patients who were using Januvia. For many, their symptoms were later resolved once they stopped taking the drug. Sorry, no compatible source and playback technology were found for this video. Try using another browser like Chrome or download the latest Adobe Flash Player. Januvia was approved by the FDA in October 2006. Between October 16, 2006 and February 9, 2009, the agency received 88 post-marketing cases of acute pancreatitis, including two cases of hemorrhagic or necrotizing pancreatitis. Sixty-six of those patients required hospitalization, and four of the patients were transferred to the intensive care unit. The FDA review of these 88 patients found that 19 Continue reading >>

Januvia Lawsuit: Pancreatic Cancer | Janumet | Classaction.org

Januvia Lawsuit: Pancreatic Cancer | Janumet | Classaction.org

Hundreds have taken legal action against Merck & Co. alleging that the companys type 2 diabetes drug Januvia puts patient at an increased risk of developing life-threatening pancreatic cancer. According to these lawsuits, Januvia is defective and unreasonably dangerous, is harmful to human health, and lacks proper warnings of the drugs dangers specifically the risk of pancreatic cancer. The plaintiffs allege that Merck & Co. knew or should have known that Januvia could cause this deadly form of cancer, and are now seeking compensation from the pharmaceutical company for medical bills, funeral expenses and other damages. What Are the Lawsuits Saying About Januvia? The plaintiffs allege that Januvia is defective, unreasonably dangerous and unsuited for its ordinary purpose because its risks outweigh its benefits. The lawsuits also allege: Merck & Co. knew, or should have known, of a causal association between Januvia and pancreatic cancer Merck & Co. failed to adequately warn the public that its type 2 diabetes drug could put patients at risk for pancreatic cancer Even if warnings were adequate, Januvia is still too dangerous for use If patients were properly warned about the pancreatic cancer risk, they would not have taken Januvia Pancreatic cancer is not even mentioned in the drugs product insert Merck & Co. continued to market and promote Januvia as a safe and effective treatment despite knowing that other, safer drugs were available Merck & Co. should withdraw Januvia from the market These plaintiffs are seeking compensation for the cost of medical bills, lost wages, and pain and suffering. While some plaintiffs are representing themselves, others are acting on a loved ones behalf, and have filed wrongful death lawsuits seeking compensation for funeral expenses and Continue reading >>

Januvia And Pancreatic Cancer

Januvia And Pancreatic Cancer

Januvia is a prescription medication used by diabetic patients to help stabilize their blood sugar levels. The drug became available for public use in 2006. However, the drug did not come without a cost, including serious side effects and an increased risk of pancreatic cancer. Have you or someone you love suffered serious side effects or an injury after taking Januvia? If so, the experienced class action attorneys at Gordon & Doner are currently investigating potential Januvia lawsuits on behalf of patients who were the victims of these serious, and sometimes fatal, side effects. Our lawyers have more than 200 years of combined legal experience and have helped victims just like you receive millions in verdicts and settlements. Contact us today to see if you are entitled to file a Januvia lawsuit and obtain compensation for medical bills, lost wages and pain and suffering. To schedule a FREE legal consultation regarding your Januvia lawsuit, call 1 (855) 722-2552 . Januvia belongs to a class of medications known as dipeptidyl peptidase-4 inhibitors (DPP-IV). It is in the same drug class as Byetta, which is also a diabetes drug that allegedly increase the risk of cancer. According to the FDA, 88 cases of acute pancreatitis among Januvia patients were reported in 2009. By 2011, this number had increased to almost two-hundred. Some of these cases resulted in death of the patient. Pancreatitis occurs when an individuals pancreas becomes inflamed. In severe cases, pancreatitis can cause permanent scarring of the pancreas, infections, cysts and internal bleeding. If left untreated, inflammation from the disease can spread to other organs, such as the heart, kidneys or lungs. Additional analysis of the FDA reports revealed that 19 of the pancreatitis cases occurred within 30 Continue reading >>

Januvia, Byetta And Victoza Lawsuits

Januvia, Byetta And Victoza Lawsuits

Judges consolidated lawsuits against the makers of Type 2 diabetes drugs Januvia, Janumet, Byetta and Victoza in MDL No. 2452 in California federal court. Plaintiffs claim drug manufacturers failed to warn about the risk of pancreatic cancer and pancreatitis. Januvia, Byetta and Victoza Lawsuit Facts DefendantsMerck, Amylin, Eli Lilly, Novo Nordisk Prescription drugs Januvia, Janumet, Byetta and Victoza are popular Type 2 diabetes treatments, but reports of dangerous side effects including pancreatitis and pancreatic cancer raised questions about whether the drugs risks outweigh their benefits. People who suffered from these side effects filed lawsuits against the makers of these drugs, Merck (Januvia and Janumet), Amylin and Eli Lilly (Byetta) and Novo Nordisk (Victoza). In May 2013, the U.S. Food and Drug Administration issued safety communications linking the drugs, collectively called incretin mimetics, to serious complications such as pancreatic diseases. The agency also advised the public it was investigating the drugs link to pancreatic cancer. After the agency stated some studies suggested a link between these drugs and pancreatic cancer, the first lawsuits alleging the drugmakers failed to warn about the risk landed in courts across the country. Federal judge in California dismissed all cases in the MDL in '15 In 2013, the United States Judicial Panel on Multidistrict Litigation (JPML) consolidated these cases in California federal court in multidistrict litigation (MDL) number 2452, In Re: Incretin Mimetics Products Liability Litigation. In November 2015, the presiding judge, Anthony J. Battaglia, granted summary judgement in favor of the defendants. Summary judgement means the judge dismissed all cases in the MDL. Plaintiffs attorneys filed an appeal in Sept Continue reading >>

Januvia Injury Lawsuits : Rottenstein Law Group Llp

Januvia Injury Lawsuits : Rottenstein Law Group Llp

Januvia Pancreatic Drug Injury & Side Effects Research shows the antidiabetic drug sitagliptin phosphatesold under the brand name Januvia and as Janumet when combined with metformincauses acute pancreatitis and pancreatic cancer. The Rottenstein Law Group, a Januvia law firm, compassionately advocates for those who have suffered Januvia side effects. If youve taken Januvia and believe it harmed you, contact RLG for a free, confidential legal consultation immediately. We will evaluate your case and remain on the lookout for Januvia recalls and Januvia class action lawsuits. What Is Januvia and What Is It Prescribed For? Januvia is the brand name for the drug sitagliptin phosphate. Made and sold by American pharmaceutical giant Merck & Co., Inc. this prescription medication is used to treat type 2 diabetes mellitus. The U.S. Food and Drug Administration (FDA) first approved Januvia in October 2006 in the form of oral tablets containing between 25 mg and 100 mg of sitagliptin phosphate. The FDA approved Janumet in 2007. Januvia is an antihyperglycemic from the dipeptidyl peptidase-4 (DPP-4) inhibitor drug class. DPP-4 is an enzyme that breaks down two types of intestinal hormones called incretins, GLP-1 and GIP. The human body releases these hormones during meals. Januvia reduces levels of the two incretins, leading to increased insulin and decreased blood sugar levels. Januvia Might Cause Acute Pancreatitis and Pancreatic Cancer On September 25, 2009, the FDA announced it was revising Januvias and Janumets label information. According to the agency, between October 2006 and February 2009, 88 people taking Janumet reported developing acute pancreatitis, and of them two had hemorrhagic or necrotizing pancreatitis. Fifty-eight of the 88 required hospitalization, of which fo Continue reading >>

More in diabetes